Top Banner
A seminar On TEST FOR TERATOGENICITY Submitted to JNTU, Hyderabad, In the partial fulfillment for the award of degree of Master of pharmacy, Department of pharmacology. PRESENTED BY M.SUMANGALI (10T21S0109) Under the guidance of Ms.Meenu singh; M.Pharm. Associate professor CMR COLLEGE OF PHARMACY Kandlakoya C.M.R COLLEGE OF PHARMACY (Approved by AICTE & PCI) (Affiliated to JNTU) Kandlakoya, Medchal.
40

Seminar on Teratogenicity by Sumaraja

Jan 15, 2015

Download

Education

Test for Teratogenicity text doc
Welcome message from author
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Page 1: Seminar on Teratogenicity by Sumaraja

A seminarOn

TEST FOR TERATOGENICITY

Submitted to JNTU, Hyderabad,In the partial fulfillment for the award of degree of Master of pharmacy, Department of

pharmacology.

PRESENTED BYM.SUMANGALI

(10T21S0109) Under the guidance of

Ms.Meenu singh; M.Pharm.Associate professor

CMR COLLEGE OF PHARMACY Kandlakoya

C.M.R COLLEGE OF PHARMACY(Approved by AICTE & PCI)

(Affiliated to JNTU)Kandlakoya, Medchal.

Page 2: Seminar on Teratogenicity by Sumaraja

CERTIFICATE

This is to certify that this is a bonafied record of the seminar entitle ”TEST FOR TERATOGENICITY” presented by Sumangali.M(10T21S0109), during the academic year 2010-2011 for partial fulfillment in degree of Masters of Pharmacy of Jawaharlal Nehru Technological University, Hyderabad.

PRINCIPAL: GUIDE:Dr. K. Rajeswar Dutt, Ms.Meenu singhM. Pharm., MBA, Ph.D. M. Pharm., (Ph.D.)

DECLARATION

I hereby declare that the seminar work entitled “TESTS FOR

TERATOGENICITY” submitted to Jawaharlal Nehru Technological University,

Hyderabad, is a record work of seminar done by me under the guidance

ofMs.Meenu singh, Associate professor of CMR College of pharmacy.

Sumangali.MReg No.10T21S0109.

Page 3: Seminar on Teratogenicity by Sumaraja

TERATOGENICITY

The capability of producing fetal malformation

INTRODUCTION

Developmental toxicity is any morphological or functional alteration caused by

chemical or physical insult that interferes with normal growth, homeostasis,

development, differentiation, and/or behavior.

Teratology is a specialized area of embryology. It is the study of the etiology of

abnormal development (the study of birth defects).

Teratogens therefore are xenobiotics and other factors that cause malformations in the

developing conceptus.

BACKGROUND

In 1956, thalidomide was introduced by Chemie Grunenthal, a West German pharmaceutical

company, as a sedative and was marketed under the name of Contergan. By 1958, it permeated

the world market, and its use expanded from simply combating insomnia. Pregnant women

frequently treated their nausea of pregnancy with thalidomide. Soon thalidomide's teratogenic

effects became apparent, and it was subsequently withdrawn from the market in 1961.

Fortunately, thalidomide had never been approved in the United States because of concerns

about the development of peripheral neuropathies. Thalidomide resurfaced in 1965 when

Sheskin, a dermatologist from Israel, made a fortuitous discovery while treating his leprosy

patients with thalidomide. He was prescribing thalidomide for its sedative properties, but he

noticed that those with erythema nodosum leprosum had resolution or improvement of their

skin lesions within 2 days of beginning treatment. This discovery has led to continued interest

and research into thalidomide's immunomodulatory activities.

Page 4: Seminar on Teratogenicity by Sumaraja

.

Page 5: Seminar on Teratogenicity by Sumaraja

TERATOGEN

A teratogen is an agent that can produce a permanent alteration of structure or

function in an organism exposed during embyronic or fetal life

Teratogens therefore are xenobiotics and other factors that cause malformations in the

developing conceptus. Examples of teratogens may include pharmaceutical compounds,

substances of abuse, hormones found in contraceptive agents, cigarette components, and

heavy metals, viral agents, altered metabolic states induced by stress, and nutrient

deficiencies (e.g., folic acid deficiency).

Basic Characteristics of teratogen

A given teratogen may be organ specific.

It may be species specific.

It can be dose specific.

Page 6: Seminar on Teratogenicity by Sumaraja

TERATOLOGY

It is the study of abnormalities of physiological development. It is often thought of as the

study of human birth defects, but it is much broader than that, taking in other non-

birth developmental stages, including puberty; and other non-human life forms,

including plants.

Principles Of Teratology

James Wilson (in 1959) proposed six principles of teratology. A simplified version of

this is as follows:

1. Susceptibility to teratogenesis depends on the embryo’s genotype that interacts with

adverse environmental factors (G × E interaction).

2. The developmental stage of exposure to the conceptus determines the outcome.

3. Teratogenic agents have specific mechanisms through which they exert there

pathogenic effects.

4. The nature of the teratogenic compound or factor determines its access to the

developing conceptus/tissue.

5. The four major categories of manifestations of altered development are

death,malformation, growth retardation, and functional deficits.

6. The manifestations of the altered development increase with increasing dose

(i.e.,no effect to lethality).

Page 7: Seminar on Teratogenicity by Sumaraja

CRITICAL PERIODS

Major fetal outcomes depend on the stage of pregnancy affected, as there are critical

periods for the development of fetal processes and organs. Although embryogenesis is

complex involving cell migrations, proliferation, differentiation, and organogenesis, one

may divide the developmental stages in to three large categories: pre-implantation,

implantation to organogenesis, and the fetal to neonatal stage. The outcomes associated

with exposure during these periods vary. This is not to say there are exceptions based on

the type of exposure. However, the primary outcomes are as follows:

STAGE OF EXPOSURE OUTCOME(S)Pre-implantation Embryonic lethality

Implantation to time of Morphological defects

organogenesis

Fetal → neonatal stage Functional disorders, growth retardation,

Carcinogenesis

The sensitivity of the embryo to the induction of morphological defects is increased during

the period of organogenesis. This period is essentially the time of the origination and

development of the organs. The critical period graph demonstrates this point and defines

the embryonic and fetal periods.

Page 8: Seminar on Teratogenicity by Sumaraja

.

Page 9: Seminar on Teratogenicity by Sumaraja

HISTORICAL TERATOGENS:

Thalidomide

Accutane

Diethylstilbestrol

Alcohol

Thalidomide

Thalidomide is a sedative-hypnotic drug used in Europe from 1957 to 1961.

It was marketed for morning sickness, nausea, and insomnia.

Women who had taken the drug from gestation days (GD) 35 to 50 gave birth to

offspring suffering from a spectrum of different malformations, mainly Amelia

(absence of limbs) or phocomelia (severe shortening of limbs).

Other malformations included: absence of the auricles with deafness, defects of the

muscles of the eye and face, and malformations of the heart, bowel, uterus, and the

gallbladder.

The compound was withdrawn from the market in 1961 after about 10,000 cases

had occurred.

Once abandoned because of devastating teratogenic effects, thalidomide has reemerged as an

alternative treatment in many dermatologic diseases. In 1998, thalidomide became FDA

approved for the acute treatment and suppression of the cutaneous manifestations of erythema

nodosum leprosum (ENL). ENL is a systemic disorder that typically occurs after several years

of antileprosy treatments, usually for lepromatous leprosy. Off-label uses for thalidomide

include: aphthous stomatitis, Behçet disease, pyoderma gangrenosum, chronic discoid lupus

erythematosus, systemic lupus erythematosus, lichen planus, prurigo nodularis and

sarcoidosis.

Page 10: Seminar on Teratogenicity by Sumaraja

Accutane (Isotetrinoin)

It is used to treate acne.

These painful and disfiguring forms of acne do not respond to other acne treatments.

Accutane is very effective, but its use is associated with a number of risks including

birth defects.

Exposure of pregnant women can lead to birth defects such as facial malformations,

heart defects, and mental retardation.

Diethylstilbestrol (DES)

From 1940 to 1970, DES was used to help maintain pregnancy.

In utero exposure to DES has been associated with abnormal development of the uterus.

It has also been associated with certain types of tumors.

Women who were exposed in utero often developed vaginal neoplasia, vaginal adenosis

and cervical erosion.

Effects were not seen in offspring until they reached puberty.

Clear cell carcinoma of the vagina is a type of adenocarcinoma found in young women

who are exposed to diethylstilbestrol in utero.

The reproductive organ of males can also be affected subsequent to in utero exposure.

The outcomes include hypotrophic testes, poor semen volume and quality.

Alcohol

Fetal Alcohol Syndrome. Fetal alcohol syndrome (FAS) is a pattern of mental and

physical defects that develops in some offspring when exposed to alcohol in utero. The

first trimester is the most susceptible period. Some babies with alcohol-related birth

defects, such as lower birth weight and body size and neurological impairments, do not

have all of the classic FAS symptoms. These outcomes are often referred to as fetal

Page 11: Seminar on Teratogenicity by Sumaraja

alcohol effects (FAE). Currently there is not total agreement among medical scientists

concerning the precise differences between

FAE and FAS. In addition to growth retardation, the most common outcomes of fetal

alcohol syndrome include psychomotor dysfunction and craniofacial anomalies.

The observed growth deficiencies are associated with an inability of the baby to catch

up due to a slower than normal rate of development. Other infrequent outcomes include

skeletal malformations such as deformed ribs and sternum, scoliosis, malformed digits,

and microcephaly.

Distinctive facial anomalies have been associated with a diagnosis of fetal alcohol

syndrome: small eye openings, epicanthal folds, failure of eyes to move in the same

direction, short upturned nose, flat or absent groove between nose and upper lip, and

thin upper lip. Visceral deformities may also be present: heart defects, genital

malformations, kidney, and urinary defects.

‘‘Non Chemical’’ Teratogens

Teratogens are not only xenobiotics. There may be other factors having the ability to cause

malformations in the developing conceptus. Restraint stress in mice (12-hour restraint during

early period of organogenesis) elicits axial skeletal defects (primarily supernumerary ribs). The

Rubella virus (first reported in 1941, Austria) is associated with a number of fetal outcomes

depending on the stage of development that the exposure occurs. Exposure during the first and

second month of pregnancy was associated with heart and eye defects. Exposure during the

third month was associated with hearing defects (and mental retardation in some cases

Page 12: Seminar on Teratogenicity by Sumaraja

TESTING PROTOCOLS

Formal testing guidelines were established after thalidomide disaster.

In 1966 guidelines were established by the FDA: Guidelines for Reproduction Studies for Safety

Evaluation of Drugs for Human Use.

Since then (1994) new streamlined testing protocols have been developed with international

acceptance. This newer approach, ICH relies on the investigator to determine the model to

access reproductive/developmental toxicity.

Under the guidelines of FDA

Multigenerational studies

Single generational studies

Segment I:Evaluation of Fertility and Reproductive Performance

Segment II: Assessment of Developmental Toxicity

Segment II: Postnatal Evaluation

Under the guidelines of ICH

Fertility Assessment

Postnatal Evaluation and Pregnancy State Susceptibility

Assessment of Developmental Toxicity

Page 13: Seminar on Teratogenicity by Sumaraja

MULTIGENERATIONAL STUDY

Rationale for the Test:

The multigeneration study was designed to detect adverse effects on the integrity and

performance of the male and female reproductive systems, including gonadal function, estrous

cycle, mating behavior, conception, gestation, parturition,lactation, and weaning, and on the

growth and development of the offspring. The adverse effects assessed in a multigeneration

study also include neonatalmortality, mortality, target organs in offspring, and functional

deficits in offspring,including behavior, maturation (puberty), and reproduction.

Principle of the Test Method:

The test article is administered to the parental animals (F 0 ) prior to and during

mating, during gestation, parturition, and lactation, and through weaning of the F 1

offspring. The test article is administered to selected F 1 offspring from weaning through

adulthood, during cohabitation and mating, and through gestation, parturition,and lactation

until the F 2 generation is weaned (PND 21).

Animal Species and Strain Selection and Rationale The rat is the commonly used species for multigeneration studies. It is generally desirable to

use the same species and strain as in other toxicological studies. If another mammalian species

is used, then justifi cation for its use should be provided in the protocol. Within and between

studies, animals should be of comparable age,weight, and parity at the start of the study. In

OECD 416, the weight variation at the commencement of study should be minimal and not

exceed 20% of the mean weight of each sex.

Page 14: Seminar on Teratogenicity by Sumaraja

Procurement and Acclimation of the Test Animals

The test animals should be young (4 – 8 weeks of age) upon arrival. The test animals should be

from the same source and strain, and the females should be nulliparous, nonpregnant, and

approximately the same age and weight. The test animals should be acclimated to the

laboratory conditions at least 5 days prior to study start.Each animal should be assigned a

unique identification number. This is done just prior to initiation of dosing for the F 0

generation and just after weaning for the F 1 generation

Number of Test Animals

The number of animals per group should be sufficient to yield not less than 20

pregnancies. Routinely, 25 male and 25 female rats per group are used. Each test group should

contain a similar number of mating pairs.

Selection of Dosage Groups, Controls, and Route of Administration:

Most multigeneration studies are designed with a vehicle control and at least three dosage

groups, all of which should be concurrent and housed and handled identically.Males and

females should be assigned by a randomization procedure that assures that mean body weights

are comparable among all test groups. The test compound and vehicle should be administered

by the route that most closely

approximates the pattern of expected human exposure. If the route of administration differs

from the expected human exposure, a justification will be required in the protocol.

Selection of Dosage Levels:

The dosage levels should be spaced to produce a gradation of toxic effects. Unless limited by

physiochemical or biological properties, the highest dose should be chosen to produce

reproductive and/or systemic toxicity. For the F 0 generation, the highest dose selected should

Page 15: Seminar on Teratogenicity by Sumaraja

not have caused greater than 10% mortality in previous toxicity studies. The intermediate dose

should only produce minimal observable toxic effects. The low dose should not produce any

evidence of either systemic or reproductive toxicity (NOAEL). Two - or fourfold intervals are

often used for spacing of the dosage levels. For dietary studies, the dosage interval should not

exceed threefold (OECD 416). Metabolism and rmacokinetics of the test article should be

available from previously conducted studies to demonstrate the adequacy of the dosing

regimen.A concurrent control group should always be used. If a vehicle control group is used,

then the dosing volume should be equal to the highest volume used. If the test article is

administered in the diet and causes reduced dietary intake, then the use of a pair - fed control

group may be necessary.

Treatment Timing and Test Duration:

The F 0 animals are dosed daily beginning at 5 – 9 weeks of age. Daily dosing of them selected

F 1 generation offspring commences at weaning. For both generations (F 0 and F 1 ) dosing

should be continued for at least 10 weeks prior to mating. Daily dosing of the F 0 and F 1

animals should continue until termination.

Mating Procedures, Detection of Mating, and Housing of Mated

Females:

A mating ratio of 1:1 from the same dosage group allows identification of both

parents of a litter. The mating pair is cohoused until evidence of copulation is

observed or either three estrous periods or 2 weeks have elapsed. Animals should be separated

as soon as evidence of copulation is observed .Once they are pregnant, females should be

housed individually to allow for monitoring of feed and, if necessary, water consumption. Feed

and water should be provided ad libitum . Pregnant animals should be provided with nesting

materials near the end of gestation.

Page 16: Seminar on Teratogenicity by Sumaraja

F 0 GENERATION

F 0 Maternal Observations

Maternal Body Weight, Feed Consumption, Behavior, and Clinical Signs

Clinical signs and mortalities should be recorded at least once daily throughout the test period.

Body weight values should be recorded on the fi rst day of dosing and at least weekly, but

during gestation and lactation body weights are routinely collected at protocol - specifi ed

intervals (e.g., GD 0, 7, 14, and 21, and LD 0, 4, 7, 14, and 21). Food consumption should be

measured at least once weekly and at the same interval as the body weight collection through

LD 14. Water consumption should be measured weekly if the test article is administered in the

drinking water. Estrous cycle length and pattern should be determined from vaginal smears

during a minimum of 3 weeks prior to mating and throughout cohabitation.

F 0 Parturition Dams should be housed in litter boxes with bedding material no

later than DG 20 (2 days prior to expected parturition, earlier if required by protocol).The

dams are observed periodically for signs of parturition onset. Individual pup observations

should not be made until delivery is completed. Dead pups should be removed from the nesting

box to preclude cannibalization by the dam.

Assessment of the F 0 Dam at Necropsy

Unscheduled Deaths Any mated females that appear moribund should be

euthanized appropriately. Any mated females that are found dead should be necropsied to

investigate the cause of death. Any evidence of pregnancy and of embryonic development

should be evaluated. A vaginal smear should be taken and the stage of estrus determined.

Scheduled Deaths All F 0 females Should be terminated when they are no longer needed for

assessment of reproductive effects. Dams are routinely necropsied on LD 21. A vaginal smear

Page 17: Seminar on Teratogenicity by Sumaraja

should be taken and the stage of estrus determined. The dam is weighed and euthanized, her

ovaries and uterus are examined, and she is subjected to a complete necropsy.

Inspection of F 0 Maternal Viscera

Unscheduled Deaths If necropsy occurs prior to parturition, then the gravid uterus

should be removed and weighed. The uterus should be examined to determine if the animal

was pregnant, and the relative numbers of live and dead conceptuses and their relative

positions in the uterus should be recorded. If the uterus shows no signs of implantation, it

should be treated with a reagent, such as 10%ammoniumsulfide, to reveal any early

resorptions. The number of corpora lutea should be recorded for each ovary, as described

earlier. The remaining maternal abdominal and thoracic organs should be inspected grossly

for evidence of toxicity. The following organs should be weighed from all F 0 females: uterus

with oviducts, ovaries, brain, pituitary, liver, kidneys, adrenal glands, spleen, and any known

target organs.The vagina, uterus with oviducts, cervix, ovaries, pituitary, and adrenal glands

should be removed, fi xed, and stored in appropriate medium for histopathological

examination. If gross organ lesions are noted, the affected organs should be preserved for

possible histopathological examination.

Scheduled Deaths If necropsy occurs as scheduled, then the uterus should be

removed and weighed. The number of corpora lutea should be recorded for each

ovary as described earlier. The remaining maternal abdominal and thoracic organs should be

inspected grossly for evidence of toxicity. The organs for organ weight collection and possible

histopathological examination are listed below. If gross organ lesions are noted, the affected

organs should be preserved for possible histopathological examination.

Histopathology for F 0 Females

The vagina, uterus with oviducts, cervix, ovaries, pituitary and adrenal glands, and any

target organs and gross lesions should be fi xed and stored in a suitable medium for

histopathological examination. Complete histological evaluation is performed on the listed

organs from ten randomly selected control and high dose F 0 females. Organs demonstrating

Page 18: Seminar on Teratogenicity by Sumaraja

treatment - related changes should be examined from the remainder of the high dose and

control animals, and for all F 0 females in the low and mid - dose groups. Additionally,

reproductive organs of the low and mid - dose females suspected of reduced fertility (those that

failed to mate, conceive, or deliver healthy offspring, or for which estrous cyclicity was

affected) should be subjected to histopathological evaluation as described previously (Segment

I). Histopathological examination should detect qualitative depletion of the primordial follicle

population; however, reproductive study guidelines require a quantitative evaluation of

primordial follicles of the F 0 females

.F 0 Paternal Observations

Paternal Body Weight, Feed Consumption, Behavior, and Clinical Signs Clinical signs and

mortalities should be recorded at least once daily. Body weight values should be recorded on fi

rst day of dosing and at least weekly thereafter. Food consumption should be measured at least

once weekly at the same interval as the body weight collection. Water consumption should be

measured weekly if the test article is administered in the drinking water.

Assessment of the F 0 Males at Necropsy

Unscheduled Deaths Any males that are found dead or appear moribund are subjected to a

complete necropsy, and their visceral contents are examined to investigate the cause of death.

Scheduled Deaths Males are routinely euthanized and necropsied after the

outcome of mating is known. In the event of an equivocal mating result, males can be mated

with untreated females to ascertain their fertility or infertility. The males treated as part of the

study may also be used for evaluation of toxicity to the male reproductive system if dosing is

continued beyond mating and sacrifi ce is delayed.

The male is weighed, euthanized, and subjected to a complete necropsy.

Inspection of F 0 Male Viscera

The testes, epididymides (paired and individually), seminal vesicles (with coagulating glands

and their fl uids), prostate, brain, pituitary, liver, kidneys, adrenal glands, spleen, and any

known target organs are removed and weighed. For all F 0 males, sperm from one testis and

one epididymis should be

Page 19: Seminar on Teratogenicity by Sumaraja

collected for enumeration of homogenization - resistant sperm and caudal epididymal sperm

reserves, respectively. In addition, sperm from one cauda epididymis (or vas deferens) should

be collected for evaluation of sperm motility and morphology.

The remaining abdominal and thoracic organs should be inspected grossly for evidence of

toxicity. If gross organ lesions are noted, the affected organs should be preserved for possible

histopathological examination.

Histopathology for F 0 Males

One testis (preserved in Bouin ’ s fi xative or a comparable preservative), one epididymis,

seminal vesicles, prostate, coagulating, pituitary, and adrenal glands, and any target organs

and gross lesions should be fi xed and stored in a suitable medium for histopathological

examination. Complete histological evaluation is performed on the listed organs from ten

randomly selected control and high dose F 0 males. Organs demonstrating treatment - related

changes should be examined from the remainder of the high dose and control animals, and

from all F 0 males in the low and mid - dose groups. Additionally, reproductive organs of the

low and mid - dose males suspected of reduced fertility (those that failed to mate or impregnate

or had abnormal sperm number, motility, or morphology) should be subjected to

histopathological evaluation as described earlier (Segment I).

F 0 Sperm Evaluation

The sperm quality parameters are sperm number, spermmotility, and sperm morphology.

Sperm evaluation will be performed on all control and high dose group F 0 males unless

treatment - related effects have been observed; in that case, the lower dosage groups should be

evaluated. The sperm evaluation methodologies were described earlier (Section 12.3.10 ). A

morphological evaluation of epididymal (or vas deferens) sperm sample should be performed.

If sperm evaluation parameters have already been evaluated as part of a systemic toxicity

study of at least 90 days ’ duration, the evaluations need not be repeated in this study.

Page 20: Seminar on Teratogenicity by Sumaraja

F 1 GENERATION

F 1 Litter Evaluations

The general appearance of the entire F 1 litter and aternal and pup nesting behavior is

observed as described earlier for Segment III.

F 1 Pup Evaluations

The litter is evaluated as soon as possible after delivery to

establish the number and sex of pups, stillbirths, live births, and the presence of gross

anomalies. Pups that are found dead should be examined for possible defects and cause of

death. Pups that have been cannibalized to the extent that their gender cannot be determined

are recorded as “ sex unable to be determined due to degree of cannibalization ”).

Live pups should be counted, sexed, and weighed individually at birth, and on LD 4,

7, 14, and 21. If a pup cannot be found during the daily litter count, the pups are sorted by

gender in order to determine the sex of the missing pup(s) by process of elimination. The

missing pup is recorded as “ missing, presumed cannibalized. ” If the pups have been tattooed

or otherwise identifi ed, the actual identifi cation number of the missing pup(s) should be

recorded.

The pup survival indices (e.g., Live Birth Index, Survival Index, and Sex Ratio) should be

calculated as described previously

Standardization of F 1 Litter Sizes

Animals should be allowed to litter normally and rear their offspring to weaning.

Standardization of litter sizes at LD 4 is optional.

Page 21: Seminar on Teratogenicity by Sumaraja

Weaning

Weaning is usually performed on LD 21. At weaning, one male and one female offspring

per litter are selected for rearing to adulthood and mating to assess reproductive competence.

Test Article Administration

The test article is administered to selected F 1 offspring from weaning through adulthood,

during cohabitation and mating, and

through gestation, parturition, and lactation until the F 2 generation is weaned.

F 1 Postweaning Developmental Landmarks

Sexual maturation landmarks are required in multigeneration studies where the selected

offspring are raised to adulthood. The OECD 416 guideline recommends that additional

developmental parameters be evaluated for supplementary information. Other functional

investigations are also recommended before and/or after weaning, such as motor activity,

sensory function, and refl ex ontogeny. These observations should not be performed on the

pups selected for mating. Described

F 1 Mating Procedure

A mating ratio of 1 : 1 from the same dosage group but from different litters allows identifi

cation of both parents of a litter. The mating pair is cohoused as described above. Pregnant

animals should be provided with nesting materials near the end of gestation. In instances of

poor reproductive performance in the controls or in the event of a treatment - related

alteration in the litter size, the adults of that generation may be remated to produce an F 1b

litter. The dams should not be remated until approximately 1 – 2 weeks following weaning of

the F 1a litter.

F 1 Maternal Observations

Maternal Body Weight, Feed Consumption, Behavior, and Clinical Signs Maternal body

weight, feed consumption, behavior, and clinical signs should be recorded at the same intervals

Page 22: Seminar on Teratogenicity by Sumaraja

as the F 0 maternal observations. Estrous cycle length and pattern should be determined from

vaginal smears during a minimum of 3 weeks prior to mating and throughout cohabitation.

Observations that have proved of value in other toxicity studies, as well as duration of

pregnancy, parturition, and nursing behaviors, are recorded.

F 1 Parturition

Dams should be housed in litter boxes with bedding material no

later than DG 20 .The dams are observed periodically throughout the day for signs of

parturition onset. As soon as the fi rst pup is found, parturition is considered initiated and

should be observed.

Assessment of F 1 Weanlings

Not Selected for Continuation At the time of termination or death during the study, when the

litter size permits, at least three pups per sex per litter should be examined macroscopically for

structural abnormalities or gross lesions, paying special attention to the reproductive organs.

Dead pups or pups that are terminated in a moribund condition should be examined for

possible defects and cause of

death. The following organs should be weighed from one randomly selected pup per sex per

litter: brain, spleen, and thymus. The following organs should be fixed and stored for

histopathological examination: gross lesions and any target organs.

Assessment of the Parental F 1 Female at Necropsy

Same as assessment of the parental f 0 female at necropsy, as described above.F 1 Male

Observations are also same.

Page 23: Seminar on Teratogenicity by Sumaraja

F 2 GENERATION

F 2 Litter and Pup Evaluations

The general appearance of the entire F 2 litter and maternal and pup nesting behavior should

be observed as described earlier for the F 1 pups. The litter is evaluated as soon as possible

after delivery to establish the number and sex of pups, stillbirths, live births, and the presence

of gross anomalies as described earlier for the F 1 pups. Live F 2 pups should be counted,

sexed, and weighed individually at birth, and on LD 4, 7, 14, and 21 as described for F 1 pups.

Pup survival indices should be calculated and reported as described earlier

Assessment of F 2 Pups at Weaning

At weaning or death during the study, when the litter size permits, at least three pups per sex

per litter should be examined macroscopically for any structural abnormalities or pathological

changes, paying special attention to the reproductive organs. Dead pups or pups that are

terminated in a moribund condition should be examined for possible defects and/or cause of

death. The following organs should be weighed from one randomly selected pup per sex per

litter: brain, spleen, and thymus. The following organs should be fixed and stored for

histopathological examination: any gross lesions and targetorgans.

Analysis of Maternal and Litter/Pup Data

Values from control and test groups of animals should be compared statistically Historical

control data should be used to enhance interpretation

of study results

Page 24: Seminar on Teratogenicity by Sumaraja

SINGLE-GENERATION STUDIES

Single-generation studies are short-term studies conducted in three segments:

Segment I:

Evaluation of Fertility and Reproductive Performance. Male rodents are treated for 70 days (to expose for one spermatogenic cycle), and nonpregnant

females for 14 days (to exposure for several estrous cycles). Treatment is continued in the

females during mating, pregnancy, and lactation. Fifty percent of the females are killed and the

fetuses are examined for presence of malformations. The other 50% are allowed to give birth.

After weaning, these offspring are killed and necropsied.

Segment II:

Assessment of Developmental Toxicity. This involves the treatment of pregnant females only during the period covering implantation

through organogenesis (typically from gestational days 6 to 15 in mice with 18-day gestational

periods). One

day prior to birth, the animals are killed and fetuses examined for viability, body weight, and

presence of malformation.

Segment III:

Postnatal Evaluation. Pregnant animals are treated from the last trimester of pregnancy until weaning. Evaluated

are parturition process, late fetal development, neonatal survival, and growth as well as

presence of any malformations.

Page 25: Seminar on Teratogenicity by Sumaraja

UNDER THE GUIDELINES OF ICH

International Conference of Harmonization (ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH)—US FDA, 1994

New streamlined testing protocols with international acceptance have been developed. Below is

a description of these guidelines as it relates to similarity to a particular segment-type study

Fertility Assessment.

This study duration is typically shorter than segment I studies. Males are exposed for four

weeks before mating and females two weeks before mating. Male reproductive organs are

carefully evaluated: organ weights, histological analysis and sperm count, and mobility

evaluation. For the females, fertility, litter size, and viability of conceptus are evaluated.

Postnatal Evaluation and Pregnancy State Susceptibility.

This study protocol is similar to the segment III study. Maternal toxicity is evaluated by

comparing the degree of toxicity of the nonpregnant female to that of the pregnant female.

Postnatal viability and growth are also evaluated. Offspring are also evaluated to assess

functional development (i.e., presence of behavioral and reproductive deficits).

Assessment of Developmental Toxicity.

Page 26: Seminar on Teratogenicity by Sumaraja

This is almost identical to the segment II study protocol. Pregnant animals are exposed from

implantation through organogenesis. The parameters measured in the segment II study are

similar. However, the study is usually conducted using at least two species. More specifically, at

least one rodent and one nonrodent species.

ALTERNATIVE TEST METHODS

A number of alternative test methods have been developed to reduce the number of whole

animals used in studies and/or to obtain more rapid information concerning the potential of a

compound to be a reproductive/developmental toxicant. Validation of many of the methods has

been problematic, since they do not address the contribution of maternal factors or multiorgan

contributions to outcomes. Some of these alternative methods include the use of cell or embryo

culture. For example, the micromass culture involves the use of limb bud cells from rat

embryos grown in micromass culture for five days. The processes of differentiation and cell

proliferation are assessed. In the Chernoff/Kavlock Assay, pregnant rodents are exposed

during organogenesis and allowed to deliver. Postnatal growth, viability, and gross

morphology of litters are recorded (detailed skeletal evaluations are not performed). Other

alternative tests involve the use of nontraditional test species such as Xenopus embryos

(FETAX) and Hydra. Xenopus embryos are exposed for 96 hours and then evaluated for

morphological defects, viability, and growth. The cells of Hydra aggregate to form artificial

embryos. The dose response in these “embryos” is compared to that of the adult Hydra.

Page 27: Seminar on Teratogenicity by Sumaraja

CONCLUSION

Understanding the mechanisms of the induction of birth defects is key to determine

how to prevent these effects. Further, increasing the accuracy of experimental animal

extrapolation will aid in the interpretation of experimental data in order to more

accurately determine the risk of a given compound to elicit birth defects in humans

Please, give only good fertilizer…

Page 28: Seminar on Teratogenicity by Sumaraja

REFERENCES

1. Modern toxicology by Earnest Hodgson Ph.D

2. Preclinical development hand book Toxicology

3. Bertram Katzung Clinical pharmacology

4. www.eurocat-network.eu

5. en.wikipedia.org/wiki/Teratology - Cached

6. www.ijp-online.com/article.asp?issn=0253-7613;year=1995;...

7. Baker, J. B. E. (1960). The effects of drugs on the foetus. Pharmac. Rev. 12, 37

Page 29: Seminar on Teratogenicity by Sumaraja

8. Brent, R. L. (1964). Drug testing in animals for teratogenic effects: thalidomide in the

pregnant rat. J. Pediat. 64,762

9. A Text book of Christie, G. A. (1962). Thalidomide and congenital abnormalities.

Lancet .1962 2, 249.

10. Giroud, A., Tuchmann-Duplessis, H. & Mercier-Parot, L. (1962). Thalidomide and

congenital abnormalities. Lancet 1962 2, 298

11. www.ncbi.nlm.nih.gov/pubmed/205663 40